Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer: a systematic review and meta-analysis

被引：7
作者：
Sun, Guijiang [1 ]
Chen, Xuanrong [1 ]
Gong, Xue [1 ]
Chen, Yawei [2 ]
Li, Guilai [3 ]
Wei, Fang [1 ]
Jiang, Aili [1 ]
Niu, Yuanjie [1 ]
Shang, Zhiqun [1 ]
机构：
[1] Tianjin Med Univ, Tianjin Inst Urol, Dept Kidney Dis & Blood Purificat Treatment, Hosp 2, Tianjin 300211, Peoples R China
[2] Chinese PLA 254 Hosp, Nephrol Dept, Tianjin 300142, Peoples R China
[3] Tianjin Med Univ, Dept Radiol, Hosp 2, Tianjin 300211, Peoples R China
来源：
FUTURE ONCOLOGY | 2019年 / 15卷 / 10期
基金：
中国国家自然科学基金;
关键词：
abiraterone; androgen deprivation therapy; chemotherapy; prostate cancer; treatment outcome; CHEMOHORMONAL THERAPY; RESISTANCE; DOCETAXEL; PROGRESSION; SURVIVAL; MEN; ADAPTATION; MECHANISMS; SELECTION; FATIGUE;
D O I：
10.2217/fon-2018-0619
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Patients with metastasis prostate cancer underwent androgen deprivation therapy (ADT) in the considering of the leading role of androgen receptor pathway. However, the resistance occurred within 1 year or more. The combination of cytotoxic chemotherapy and abiraterone for ADT therapy was performed in recent randomized controlled trials. The meta-analysis was focused on the treatment comparisons between additional treatment with ADT and ADT alone. A significant difference was observed that the overall survival benefit of early and active additional treatment with ADT in patients with hormone-sensitive metastatic prostate cancer. However, a great proportion of patients with metastatic disease have metastases after receiving ADT. It will be important to further improve the treatment options.
引用
收藏
页码：1167 / 1179
页数：13
相关论文
共 37 条
[1]   Adaptation and clonal selection models of castration-resistant prostate cancer: Current perspective [J].
Ahmed, Muhammed ;
Li, Long-Cheng .
INTERNATIONAL JOURNAL OF UROLOGY, 2013, 20 (04) :362-371
[2]   How to obtain the P value from a confidence interval [J].
Altman, Douglas G. ;
Bland, J. Martin .
BMJ-BRITISH MEDICAL JOURNAL, 2011, 343
[3]   Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer [J].
Antonarakis, Emmanuel S. ;
Lu, Changxue ;
Luber, Brandon ;
Wang, Hao ;
Chen, Yan ;
Nakazawa, Mary ;
Nadal, Rosa ;
Paller, Channing J. ;
Denmeade, Samuel R. ;
Carducci, Michael A. ;
Eisenberger, Mario A. ;
Luo, Jun .
JAMA ONCOLOGY, 2015, 1 (05) :582-591
[4]   AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer [J].
Antonarakis, Emmanuel S. ;
Lu, Changxue ;
Wang, Hao ;
Luber, Brandon ;
Nakazawa, Mary ;
Roeser, Jeffrey C. ;
Chen, Yan ;
Mohammad, Tabrez A. ;
Chen, Yidong ;
Fedor, Helen L. ;
Lotan, Tamara L. ;
Zheng, Qizhi ;
De Marzo, Angelo M. ;
Isaacs, John T. ;
Isaacs, William B. ;
Nadal, Rosa ;
Paller, Channing J. ;
Denmeade, Samuel R. ;
Carducci, Michael A. ;
Eisenberger, Mario A. ;
Luo, Jun .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) :1028-1038
[5]   New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway [J].
Attard, Gerhardt ;
Richards, Juliet ;
de Bono, Johann S. .
CLINICAL CANCER RESEARCH, 2011, 17 (07) :1649-1657
[6]   Targeting molecular resistance in castration-resistant prostate cancer [J].
Chandrasekar, Thenappan ;
Yang, Joy C. ;
Gao, Allen C. ;
Evans, Christopher P. .
BMC MEDICINE, 2015, 13
[7]   Abiraterone and Increased Survival in Metastatic Prostate Cancer [J].
De Bono, Johann S. ;
Logothetis, Christopher J. ;
Molina, Arturo ;
Fizazi, Karim ;
North, Scott ;
Chu, Luis ;
Chi, Kim N. ;
Jones, Robert J. ;
Goodman, Oscar B., Jr. ;
Saad, Fred ;
Staffurth, John N. ;
Mainwaring, Paul ;
Harland, Stephen ;
Flaig, Thomas W. ;
Hutson, Thomas E. ;
Cheng, Tina ;
Patterson, Helen ;
Hainsworth, John D. ;
Ryan, Charles J. ;
Sternberg, Cora N. ;
Ellard, Susan L. ;
Flechon, Aude ;
Saleh, Mansoor ;
Scholz, Mark ;
Efstathiou, Eleni ;
Zivi, Andrea ;
Bianchini, Diletta ;
Loriot, Yohann ;
Chieffo, Nicole ;
Thian Kheoh ;
Haqq, Christopher M. ;
Scher, Howard I. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :1995-2005
[8]   Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis [J].
Feyerabend, Susan ;
Saad, Fred ;
Li, Tracy ;
Ito, Tetsuro ;
Diels, Joris ;
Van Sanden, Suzy ;
De Porre, Peter ;
Roiz, Julie ;
Abogunrin, Seye ;
Koufopoulou, Maria ;
Fizazi, Karim .
EUROPEAN JOURNAL OF CANCER, 2018, 103 :78-87
[9]   Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer [J].
Fizazi, Karim ;
NamPhuong Tran ;
Fein, Luis ;
Matsubara, Nobuaki ;
Rodriguez-Antolin, Alfredo ;
Alekseev, Boris Y. ;
Ozguroglu, Mustafa ;
Ye, Dingwei ;
Feyerabend, Susan ;
Protheroe, Andrew ;
De Porre, Peter ;
Kheoh, Thian ;
Park, Youn C. ;
Todd, Mary B. ;
Chi, Kim N. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04) :352-360
[10]   Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study [J].
Gerritse, F. L. ;
Meulenbeld, H. J. ;
Roodhart, J. M. L. ;
van der Velden, A. M. T. ;
Blaisse, R. J. B. ;
Smilde, T. J. ;
Erjavec, Z. ;
de Wit, R. ;
Los, M. .
EUROPEAN JOURNAL OF CANCER, 2013, 49 (15) :3176-3183
1234